Adverum Biotechnologies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADVM Nasdaq 8731 https://adverum.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adverum Biotechnologies Inc

Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD - Jun 24th, 2022 12:00 pm
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD - Jun 9th, 2022 12:00 pm
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting - Jun 2nd, 2022 8:05 pm
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy - May 19th, 2022 12:00 pm
Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy - May 18th, 2022 12:11 pm
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022 - May 17th, 2022 8:05 pm
Adverum Biotechnologies Reports First Quarter 2022 Financial Results - May 12th, 2022 8:05 pm
How Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own? - May 11th, 2022 6:51 pm
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 9th, 2022 8:05 pm
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022 - May 2nd, 2022 8:30 pm
Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD - May 2nd, 2022 10:59 am
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting - May 1st, 2022 6:15 pm
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022 - Apr 19th, 2022 10:00 pm
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study - Apr 7th, 2022 6:50 pm
Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD - Apr 7th, 2022 11:30 am
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA - Apr 6th, 2022 8:05 pm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results - Mar 29th, 2022 8:05 pm
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors - Mar 17th, 2022 8:05 pm
Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings? - Mar 2nd, 2022 5:11 pm
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference - Feb 28th, 2022 1:00 pm